Hydrogen selenide (H2Se) as one of the endogenous gaseous signaling molecules for antibacterial gas therapy, faces limitations such as high‐dose toxicity and short half‐life. Herein, a polymeric H2Se delivery nanogel (H2Se‐NG) incorporated with aldehyde‐modified selenobenzamide (SeAs) is designed for multidrug resistant (MDR) related healthcare‐associated infections (HAIs) treatment. H2Se‐NG facilitates a dual‐cascade responsive release of H2Se over 72 h, effectively addressing the safety issues caused by the rapid hydrolysis of traditional inorganic H2Se delivery methods. In vitro and in vivo studies demonstrate that nontoxic doses of H2Se‐NG at 150 µg mL−1 not only eliminated over 99% of MDR bacteria and their biofilm within 8 h while reducing levels of proinflammatory cytokines postinfection. Additionally, RNA sequencing results reveal that the released H2Se induces oxidative stress at infection site, kills biofilm‐embedded methicillin‐resistant Staphylococcus aureus (MRSA) and leads biofilm elimination by activating biofilm dispersion genes, suggesting the potential of H2Se‐NG as a promising strategy in antibacterial gas therapy.